Skip to main content
. 2015 Oct;355(1):99–107. doi: 10.1124/jpet.115.226373

TABLE 2.

Xenobiotic-induced cytotoxicity in LLC-vector and LLC-MDR1-WT cells

LLC-PK1 Cellsa EC50 Values (95% Confidence Interval)
LLC-Vector Cellsb LLC-MDR1-WT Cellsb
Doxorubicin (nM)c 32.2 (13.7–85.6) 1978 (1015–3850)***
 + GF120918c 24.8 (12.0–51.3) 8.06 (1.32–49.2)†††
 + Verapamilc 43.4 (12.0–155.9) 268 (90.7–98.6)†††
Colchicine (nM)c 13.3 (N.D.)d 645 (467–892)
 + GF120918c 12.6 (10.8–14.5) 17.5 (12.0–25.4)†††
 + Verapamilc 12.8 (N.D.)d 179 (117–273)†††
Ivermectin (µM) 4.86 (4.51–5.23) 4.04 (3.76–4.35)***
 + GF120918 5.76 (5.33–6.23)†† 4.59 (3.99–5.28)
 + Verapamil 3.99 (3.31–4.81) 4.25 (4.02–4.50)
Diazinon (µM) 1789 (N.D.)d 384 (279–528)
 + GF120918 132 (68.1–255) 414 (165–1040)
 + Verapamil 592 (50.6–6920) 373 (159–877)
Dieldrin (µM) 51.4 (41.1–64.4) 75.4 (62.9–90.4)*
 + GF120918 38.2 (28.0–52.0) 70.7 (57.0–87.6)
 + Verapamil 33.0 (27.3–39.8) 40.0 (32.4–49.4)†††
Endosulfan (µM) 14.0 (10.4–18.8) 19.4 (12.5–30.2)
 + GF120918 17.4 (11.6–26.0) 40.7 (16.9–98.0)
 + Verapamil 8.40 (5.01–14.1) 16.8 (10.7–26.4)
Maneb (µM) N.D.d 40.3 (32.7–49.6)
 + GF120918 24.6 (13.9 – 43.7) 37.7 (30.0–47.3)
 + Verapamil N.D.d 39.2 (32.9–46.7)
MPP+ (µM) 27.1 (16.7–43.9) 418 (170–1030)***
 + GF120918 84.9 (37.1–194) 566 (299–1070)
 + Verapamil 31.9 (18.1–56.2) 69.0 (39.4–121)††
Rotenone (nM) 12.5 (7.9–19.8) 27.7 (21.7–35.3)**
 + GF120918 17.4 (12.7–23.8) 35.0 (23.5–52.1)
 + Verapamil 5.89 (3.97–8.73) 7.24 (4.50–11.6)†††

N.D., not determined.

a

Significant differences between cell types in the xenobiotic treatment alone group; *P < 0.05, **P < 0.01, and ***P < 0.001.

b

Significant differences within a cell type between the xenobiotic treatment alone group and in the presence of a P-gp inhibitor; P < 0.05, ††P < 0.01, and †††P < 0.001.

c

Doxorubicin and colchicine have been reported previously (Lacher et al., 2014).

d

Nonlinear regression was unable to estimate confidence intervals.